US diagnostic firm CorePlus has announced the implementation of AIxURO, a state-of-the-art software solution that utilises artificial intelligence to significantly improve the accuracy and efficiency of bladder cancer detection.
The innovative platform enhances traditional urine cytology analysis, providing faster, more precise diagnostics. The result of a collaboration with AIxMed, a healthcare firm developing AI technologies, AIxURO joins CorePlus's portfolio of precision diagnostic tools and underscores the company's commitment to addressing critical health challenges through advanced technology.
AIxURO is designed to address the challenges associated with conventional urine cytology by leveraging AI to pre-screen and identify suspicious and atypical cells. The software analyses whole slide images and presents abnormal cells in a streamlined gallery view, following The Paris System for reporting urinary cytology. By combining qualitative morphology with quantitative metrics, AIxURO assists pathologists in making more confident diagnostic decisions, which can lead to earlier and more effective patient treatment.
"This achievement represents the culmination of over two years of dedicated collaboration and innovation. Through persistence and precision, our teams have developed and integrated an AI algorithm that meets the highest standards for clinical use. CorePlus continues to advance its mission of transforming patient care through precision pathology, turning years of research into real life impact for patients," said Mariano de Socarraz, Founder and CEO of CorePlus. “Together with AIxMed, we have refined every aspect of the process to ensure clinical precision and reproducibility at scale. The AIxURO urine cytology algorithm embodies the rigorous standards we envisioned and uphold at CorePlus,” he added.
Juan C Santa Rosario MD, pathologist, and CorePlus' Chief Medical Officer added: "The algorithm has undergone extensive validation across diverse sample sets, demonstrating consistent accuracy and reproducibility aligned with established diagnostic standards. This achievement underscores the value of multi-disciplinary collaboration between pathologists, cytologists, engineers, and data scientists - transforming AI from an experimental tool into a dependable component of diagnostic medicine."
By enabling pathologists to identify abnormalities with greater accuracy and efficiency, AIxURO ultimately enhances the patient care pathway. The result is earlier detection of potential urinary tract malignancies, leading to quicker intervention and improved outcomes. Patients benefit from reduced diagnostic uncertainty, less invasive follow-up procedures when unnecessary, and the reassurance that advanced technology is being utilised in their care. This innovative approach not only supports better clinical decisions but also promotes peace of mind and trust in the diagnostic process.
A key benefit of the AIxURO platform is its ability to reduce diagnostic review time by 50-80%, accelerating the delivery of results. By analysing non-invasive urine samples with high accuracy, it also reduces the need for frequent and invasive cystoscopy procedures, improving patient compliance and lowering overall healthcare costs.